What is the recommended dose and titration schedule for tricyclic antidepressants (e.g., amitriptyline, nortriptyline) for treating sciatica?

Tricyclic Antidepressants for Sciatica: Dosing and Medication Selection

For sciatica (lumbar radiculopathy), start with nortriptyline 25 mg at bedtime, increase by 25 mg every 3-7 days as tolerated up to 150 mg/day maximum, and allow 6-8 weeks for an adequate trial with at least 2 weeks at the maximum tolerated dose. 1

Preferred Medication: Nortriptyline Over Amitriptyline

Nortriptyline or desipramine (secondary-amine TCAs) are preferred over amitriptyline (tertiary-amine TCA) for neuropathic pain conditions including sciatica 1. The guidelines explicitly state to use tertiary amine TCAs only if secondary amine TCAs are not available. This preference is based on the better side effect profile of secondary amines, though both classes can be effective.

Specific Dosing Protocol

Starting Dose

• Nortriptyline: 25 mg at bedtime 1
• If using amitriptyline (when nortriptyline unavailable): Start with 10-25 mg at bedtime 2

Titration Schedule

• Increase by 25 mg every 3-7 days as tolerated 1
• Make increases preferably in the late afternoon and/or bedtime doses 2
• In geriatric patients, use lower starting doses and slower titration 1

Maximum Dose

• 150 mg/day for nortriptyline 1
• If blood concentration of active medication and its metabolite is <100 ng/mL, continue titration with caution beyond 150 mg 1
• For amitriptyline: outpatients typically use 75-150 mg/day; hospitalized patients may require up to 200-300 mg/day 2

Duration of Adequate Trial

• 6-8 weeks total, with at least 2 weeks at the maximum tolerated dose 1
• A sedative effect may appear before the antidepressant/analgesic effect, which may take up to 30 days to develop 2

Evidence Specific to Sciatica

The evidence for TCAs in sciatica specifically is limited. One high-quality RCT found that nortriptyline (25-100 mg) showed only 14% pain reduction relative to placebo in chronic sciatica patients, which was not statistically significant 3. However, this study had significant limitations including a high dropout rate (only 28 of 61 patients completed) and the mean dose achieved was 84 mg/day, suggesting many patients didn't reach optimal dosing.

Despite this negative trial, TCAs remain guideline-recommended first-line agents for neuropathic pain broadly 1, and retrospective data suggests patients with both leg and back pain (typical of sciatica) may respond better than those with back pain alone 4.

Practical Considerations

Dosing in Real-World Practice

• Most patients in specialty pain practice use 10-25 mg daily and experience benefit at these low doses 5
• Approximately 75% of patients report improvement, with 85% still taking medication at follow-up 5
• Low-dose therapy (10-25 mg) may improve medication persistence while maintaining efficacy 5

Common Side Effects

• Daytime fatigue (most common), dry mouth, dizziness, constipation, urinary retention 6
• Amitriptyline and doxepin appear to cause more side effects than nortriptyline, desipramine, and imipramine 7
• 27-28% of patients experience new harms by day 14 6

Monitoring

• A sedative effect may be apparent before analgesic benefit 2
• In elderly patients, plasma levels are generally higher for a given dose due to increased intestinal transit time and decreased hepatic metabolism 2
• Consider quantitative serum levels if toxicity is suspected or lack of absorption/noncompliance is a concern 2

Clinical Algorithm

1. First choice: Nortriptyline 25 mg at bedtime
2. Increase by 25 mg every 3-7 days based on tolerability
3. Target dose: 75-100 mg/day (though many patients respond to 10-25 mg)
4. Maximum: 150 mg/day (can exceed with caution if blood levels <100 ng/mL)
5. Allow 6-8 weeks for full trial with at least 2 weeks at maximum tolerated dose
6. If nortriptyline unavailable: Use amitriptyline with same titration schedule
7. In elderly patients: Start lower (10 mg) and titrate more slowly

Important Caveats

• The evidence for TCAs specifically in sciatica is weak 3, though they remain guideline-recommended for neuropathic pain generally
• High dropout rates are common in clinical trials, suggesting tolerability issues in real-world practice
• Benefits may occur at lower doses than traditionally studied (10-25 mg vs 75-150 mg) 5
• Once-daily bedtime dosing is preferred and may improve outcomes compared to divided doses 8
• Consider alternative first-line agents (gabapentin, pregabalin, duloxetine) if TCAs are poorly tolerated or contraindicated 1